期刊文献+

二甲双胍联合荷丹片对非酒精性脂肪性肝病生化指标的影响 被引量:4

Effect of metformin combined with hedan tablets on biochemical indicators of non-alcoholic fatty liver disease
在线阅读 下载PDF
导出
摘要 目的探讨二甲双胍联合荷丹片治疗非酒精性脂肪性肝病(NAFLD)的疗效。方法将100例NAFLD患者随机分为实验组和对照组,每组50例。实验组采取二甲双胍联合荷丹片的治疗方法,对照组采取荷丹片单独治疗。结果治疗后,两组病情均有一定程度的好转。与对照组相比,实验组AST、ALT、TG、TC等指标明显改善,总有效率为94%(P<0.05)。两组不良反应比较,差异无统计学意义。结论二甲双胍联合荷丹片治疗NAFLD较单用荷丹治疗效更佳,值得临床推广。 Objective To discuss the effect of metformin combined with hedan tablets in the treatment for non-alcoholic fatty liver disease (NAFLD). Methods 100 NAFLD patients were randomly divided into experimental group and control group,50 cases in each group. Patients of experimental group were given metformin combined with hedan tablets, and control group was only given hedan tablets. Results After treatment, the condition of both experimental group and control group had certain improvement. Compared with control group, the AST, ALT, TG, TC and other indicators of experimental group were improved more effectively. The total effective rate of experimental group was better than that of control group(94% vs. 76% ,P 〈 0. 05 ). The adverse reactions had no singnificant difference between the two groups. Conclusion Metformin combined with hedan tablets in the treatment for non-alcoholic fatty liver disease is a better way than single use, and it is worthy of promotion.
作者 李兴涛 王敏
出处 《实用药物与临床》 CAS 2012年第10期630-632,共3页 Practical Pharmacy and Clinical Remedies
关键词 二甲双胍 荷丹片 非酒精性脂肪性肝病 肝硬化 Metformin Hedan tablets Non-alcoholic fatty liver disease Cirrhosis
  • 相关文献

参考文献13

二级参考文献127

共引文献1814

同被引文献41

  • 1沈峰,丁晓东,范建高.2012美国非酒精性脂肪性肝病诊疗指南简介[J].中国医学前沿杂志(电子版),2012,4(7):11-13. 被引量:33
  • 2昌炳如.高脂血症的病因病机与治疗探讨[J].中医研究,2005,18(8):3-5. 被引量:33
  • 3Sanyal AJ.NASH:A global health problem[J].Hepatol Res,2011,41(7):670-674.
  • 4Treeprasertsuk S,Lopez-Jimenez F,Lindor KD.Nonalcoholic fatty liver disease and the coronary artery disease[J].Dig Dis Sci,2011,56(1):35-45.
  • 5Pais R,Ratziu V.Epidemiology and natural history of nonalcoholic fatty liver disease[J].Rev Prat,2012,62(10):1416-1418,1420-1421.
  • 6Gariani K,Philippe J,Jornayvaz FR.Non-alcoholic fatty liver disease and insulin resistance:from bench to bedside[J].Diabetes Metab,2013,39(1):16-26.
  • 7Gnacińska M,Magorzewicz S,Lysiak-Szyd owska W,et al.The serum profile of adipokines in overweight patients with metabolic syndrome[J].Endokrynol Pol,2010,61(1):36-41.
  • 8Machado MV,Cortez-Pinto H.Gut microbiota and nonalcoholic fatty liver disease[J].Ann Hepatol,2012,11(4):440-449.
  • 9Musso G,Cassader M,Rosina F,et al.Impact of current treatments on liver disease,glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD):a systematic review and meta-analysis of randomised trials[J].Diabetologia,2012,55(4):885-904.
  • 10Lomonaco R,Chen J,Cusi K.An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD)[J].Ther Adv Endocrinol Metab,2011,2(5):211-225.

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部